ATE165977T1 - Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie - Google Patents

Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie

Info

Publication number
ATE165977T1
ATE165977T1 AT93902861T AT93902861T ATE165977T1 AT E165977 T1 ATE165977 T1 AT E165977T1 AT 93902861 T AT93902861 T AT 93902861T AT 93902861 T AT93902861 T AT 93902861T AT E165977 T1 ATE165977 T1 AT E165977T1
Authority
AT
Austria
Prior art keywords
analgesia
enhancement
methods
opiate
producing
Prior art date
Application number
AT93902861T
Other languages
English (en)
Inventor
Alan Justice
Tejinder Singh
Kishor Chandra Gohil
Karen L Valentino
George P Miljanich
Original Assignee
Neurex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurex Corp filed Critical Neurex Corp
Application granted granted Critical
Publication of ATE165977T1 publication Critical patent/ATE165977T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93902861T 1991-12-30 1992-12-30 Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie ATE165977T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81475991A 1991-12-30 1991-12-30

Publications (1)

Publication Number Publication Date
ATE165977T1 true ATE165977T1 (de) 1998-05-15

Family

ID=25215938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93902861T ATE165977T1 (de) 1991-12-30 1992-12-30 Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie

Country Status (8)

Country Link
US (3) US5587454A (de)
EP (1) EP0625162B1 (de)
AT (1) ATE165977T1 (de)
AU (1) AU689438B2 (de)
CA (1) CA2151741C (de)
DE (1) DE69225499T2 (de)
SG (1) SG50624A1 (de)
WO (1) WO1993013128A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824645A (en) * 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
EP1336409B1 (de) * 1995-06-27 2007-04-11 Eisai R&D Management Co., Ltd. Zusammensetzungen zur Erzielung von Analgesie und zur Hemmung der Progression neuropathischer Schmerzerkrankungen
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU6454096A (en) * 1995-07-26 1997-02-26 Warner-Lambert Company Use of neuronal calcium channel blockers for the manufacture of a medicament for the treatment of psychoses, schizophrenia and cocaine or amphetamine addiction
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US6060271A (en) * 1996-02-09 2000-05-09 Cornell Research Foundation, Inc. CDNA fragments corresponding to voltage gated sodium channel genes expressed in peripheral nerve
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6489119B1 (en) * 1996-03-29 2002-12-03 Elan Pharmaceuticals, Inc. Analgesic screening method and composition
EP0985667A4 (de) 1997-04-25 2000-03-22 Ajinomoto Kk Neue dihydropyridin-derivate
US5844077A (en) 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
EP1014959B1 (de) * 1997-08-15 2004-10-20 Carolyn Ann Fairbanks Agmatin für die behandlung neuropathischer schmerzen
CA2224066A1 (en) 1997-10-24 1999-04-24 Universite D'ottawa/ University Of Ottawa Peptides as analgesics
WO1999032446A1 (en) 1997-12-22 1999-07-01 Ajinomoto Co., Inc. Novel dihydropyridine derivative
US7101849B1 (en) * 1998-04-16 2006-09-05 The University Of Queensland ωconotoxin peptides
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6369193B1 (en) * 1998-10-20 2002-04-09 University Of Utah Research Foundation Contulakin-G, analogs thereof and uses therefor
WO2000043409A2 (en) 1999-01-22 2000-07-27 University Of Utah Research Foundation Alpha-conotoxin peptides
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
AU5568300A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyridine derivative
WO2000078730A1 (en) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
AU5568200A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Dihydropyridine derivative
EP1210100B1 (de) 1999-08-10 2006-06-14 UAB Research Foundation Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten
WO2001049312A2 (en) * 1999-12-30 2001-07-12 University Of Utah Research Foundation O-superfamily conotoxin peptides
US20030119731A1 (en) * 2000-07-21 2003-06-26 University Of Utah Research Foundation Omega-conopeptides
EP1311283A4 (de) * 2000-07-21 2004-09-01 Univ Utah Res Found Omega-conopeptide
DE60236496D1 (de) * 2001-03-23 2010-07-08 Einstein Coll Med Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1496911B1 (de) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
EP2412719A1 (de) 2002-12-02 2012-02-01 Xenome Ltd Chi-Conotoxin-Peptide
WO2004050690A1 (en) * 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
EP1911763B1 (de) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7365050B2 (en) * 2003-08-08 2008-04-29 The Regents Of The University Of California Methods for modulating a drug-related effect or behavior
CA2540895C (en) * 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
US8022177B2 (en) * 2005-09-30 2011-09-20 The Board Of Trustees Of The University Of Illinois Peptides and calcium regulation in mammalian cells
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels
EP1963280B1 (de) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylaminoderivate als calcium- und/oder natrium-kanalmodulatoren
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2689561C (en) 2007-06-15 2015-11-17 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
PT2723710T (pt) 2011-06-27 2016-11-14 Newron Pharm Spa Derivados fluorados de arilalquilaminocarboxamida
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
EP3930702A1 (de) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyratzusammensetzungen mit verbesserter pharmakokinetik im zugeführten zustand
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US5196204A (en) * 1986-10-20 1993-03-23 University Of Utah Research Foundation Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5189020A (en) * 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5231011A (en) * 1991-04-18 1993-07-27 University Of Utah Segregated folding determinants for small disulfide-rich peptides

Also Published As

Publication number Publication date
CA2151741A1 (en) 1993-07-08
US5859186A (en) 1999-01-12
EP0625162A1 (de) 1994-11-23
HK1013832A1 (en) 1999-09-10
US5364842A (en) 1994-11-15
DE69225499T2 (de) 1999-02-04
EP0625162B1 (de) 1998-05-13
WO1993013128A1 (en) 1993-07-08
US5587454A (en) 1996-12-24
DE69225499D1 (de) 1998-06-18
SG50624A1 (en) 1998-07-20
AU3428093A (en) 1993-07-28
CA2151741C (en) 2001-12-11
AU689438B2 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
ATE165977T1 (de) Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
DE69419152D1 (de) Verfahren zur herstellung von mischungen von n-acylierten aminosaeuren
DE3177260D1 (de) Fuer plasminogen-aktivator kodierende rekombinante desoxyribonukleinsaeure und verfahren zur herstellung von plasminogen-aktivator-protein daraus.
DE69434703D1 (de) Verfahren zur Erzeugung von DSA-Unterschriften mit preisgünstigen tragbaren Einheiten
DE68928934D1 (de) Verfahren zur herstellung von menschlicher dnase
DE59000200D1 (de) Verfahren zur gewinnung von erdgas.
ATE326476T1 (de) Verfahren zur herstellung von phosphorothioat- oligomeren
ATE125157T1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DE59611165D1 (de) Verfahren zur Herstellung von Ausweiskarten
DE69432704D1 (de) Verfahren zur Herstellung von humanen Relaxin
DE69813212D1 (de) Verfahren zur erzeugung von proteinhydrolysaten
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ATE265529T1 (de) Bmp-10 zusammensetzungen
EP1023451A4 (de) Methoden zur replikation von viren in von monozyten abgeleiteten makrophagenkulturen
DE3583896D1 (de) Verfahren und vorrichtung zur herstellung von weissen zementklinkern.
DE3751179D1 (de) Peptide, die die Bindung des Von-Willebrand-Faktors inhibieren.
ATE184917T1 (de) Rekombinante methode und wirt zur herstellung von xylitol
DE69129115D1 (de) Neues verfahren zur behandlung von depression
DE69407272D1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
ATE71109T1 (de) Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung.
ATE204291T1 (de) Verfahren zur herstellung von peptiden und n- carbamoyl-geschützten peptiden
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE3853156D1 (de) Polyestergewebe zur herstellung von elektrophoresegelen und elektrophoresegel.
DE3881685D1 (de) Kombiniertes verfahren zur erzeugung von chlordioxid und natriumhydroxid.
ATE80594T1 (de) Verfahren zur herstellung von boriden der seltenen erden.